Clinical trial · Interventional
Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
HUGO RAS Robotic Platform for Radical Prostatectomy and Partial Nephrectomy: Comparison with the Da Vinci Robotic Platform
NCT06844513CI-TRIAL-00086428URO-ROBOT-2023not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed as a single-center, prospective, interventional, non-pharmacological, randomized, open-label, controlled trial with parallel groups. It targets patients with prostate cancer or kidney cancer who are candidates for robot-assisted surgical treatment, specifically radical prostatectomy (RP) or partial nephrectomy (PN).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer (Adenocarcinoma) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Renal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Partial nephrectomy | Procedure | — | UNRESOLVED |
| Radical prostatectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- prostate cancer
- description
- Patients with prostate cancer (Group A), enrolled according to the inclusion criteria, are randomized to undergo radical prostatectomy (RP) using either the Da Vinci Xi platform (control group) or the HUGO™ RAS platform (study group).
- interventionNames
- Procedure: Radical prostatectomy
- type
- ACTIVE_COMPARATOR
- label
- kidney cancer
- description
- patients with kidney cancer (Group B), enrolled according to the inclusion criteria, are randomized to undergo partial nephrectomy (PN) using either the Da Vinci Xi platform or the HUGO™ RAS platform.
- interventionNames
- Procedure: Partial nephrectomy
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients with Prostate Cancer (Group A) * Age ≥ 18 years. * Life expectancy greater than 10 years. * Diagnosis of prostate cancer following prostate needle biopsy. * Clinical stage cT1-T3b, N0-1 disease. * Positive anesthetic fitness assessment for robot-assisted radical prostatectomy. * Provision of informed consent for the study. Patients with Kidney Cancer (Group B) * Age ≥ 18 years. * Radiological diagnosis of organ-confined kidney cancer at clinical stage T1a or T1b. * Underwent CT and/or MRI of the abdomen with contrast medium. * Positive anesthetic fitness assessment for robot-assisted partial nephrectomy. * Provision of informed consent for the study. Exclusion Criteria: Patients with Prostate Cancer (Group A) * Expression of a preference for radical treatment other than surgery (e.g., external radiotherapy). * Metastatic prostate cancer (M1). * Other conditions deemed by healthcare professionals to contraindicate inclusion in the study. Patients with Kidney Cancer (Group B) * Indication for radical nephrectomy. * Metastatic kidney cancer (M1). * Other conditions deemed by healthcare professionals to contraindicate inclusion in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.